486 related articles for article (PubMed ID: 21262381)
1. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
2. Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Fan Y; Peng A; He S; Shao X; Nie C; Chen L
J Chemother; 2013 Oct; 25(5):298-308. PubMed ID: 24070138
[TBL] [Abstract][Full Text] [Related]
3. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
4. Novel angiogenesis inhibitors: addressing the issue of redundancy in the angiogenic signaling pathway.
Ribatti D
Cancer Treat Rev; 2011 Aug; 37(5):344-52. PubMed ID: 21435792
[TBL] [Abstract][Full Text] [Related]
5. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Loges S; Mazzone M; Hohensinner P; Carmeliet P
Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic agents and targets: A perspective.
Teicher BA
Biochem Pharmacol; 2011 Jan; 81(1):6-12. PubMed ID: 20920481
[TBL] [Abstract][Full Text] [Related]
8. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
9. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
Osada H; Kakeya H
Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
[TBL] [Abstract][Full Text] [Related]
10. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC; Leenders WP
Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
[TBL] [Abstract][Full Text] [Related]
11. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
12. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
Tandle A; Libutti SK
Clin Adv Hematol Oncol; 2003 Jan; 1(1):41-8. PubMed ID: 16227959
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic phytochemicals and medicinal herbs.
Jeong SJ; Koh W; Lee EO; Lee HJ; Lee HJ; Bae H; Lü J; Kim SH
Phytother Res; 2011 Jan; 25(1):1-10. PubMed ID: 20564543
[TBL] [Abstract][Full Text] [Related]
15. [The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?].
Grépin R; Pagès G
J Soc Biol; 2009; 203(2):181-92. PubMed ID: 19527632
[TBL] [Abstract][Full Text] [Related]
16. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH; Tzakos A; Zografos G
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
[No Abstract] [Full Text] [Related]
17. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor receptors: expression and function in solid tumors.
Wey JS; Stoeltzing O; Ellis LM
Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
20. [Development of novel angiogenesis inhibitors targeting VEGF (vascular endothelial growth factor) for cancer chemotherapy].
Kakeya H; Osada H
Nihon Rinsho; 2004 Jul; 62(7):1264-70. PubMed ID: 15283142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]